A Phase 3 interventional study of Sotagliflozin and Empagliflozin in Type 2 Diabetes Mellitus, sponsored by Lexicon Pharmaceuticals. Completed at 160 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-11.
Sponsored by Lexicon Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. sotagliflozin · Diabetes Mellitus, Type 2.
Among the 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is one of 9 that started in 2017, is one of 13 in phase 3, and was the 18th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Baylor Research Institute · Sites in United States
Ages 18–84
Allied Hospital Faisalabad · Sites in Pakistan
Ages 30–65
AdventHealth Translational Research Institute · Sites in United States
Ages 18–40 · Healthy volunteers
By country, each count listing its studies:
sotagliflozin: first FDA approval 2023 (INPEFA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 9 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 770 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 208 across the 28 interventional studies. Of the 25 that completed or were terminated, 13 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 28 have an industry lead sponsor. The 5 most frequent:
Lexicon Pharmaceuticals is the lead sponsor of 61 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 15 (83%) have results posted.
17 studies in Diabetes Mellitus, Type 2 by Lexicon Pharmaceuticals: none open now, none under way, none of them phase 3. Of 17 finished, 13 (76%) have results posted.
Among the 17 studies in Diabetes Mellitus, Type 2 by Lexicon Pharmaceuticals, this one is the 5th largest by enrollment, is one of 7 that started in 2017, is one of 11 in phase 3, and was the 15th registered.
Lexicon Pharmaceuticals’s Diabetes Mellitus, Type 2 studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among Lexicon Pharmaceuticals’s 17 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to demonstrate the superiority of sotagliflozin versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control on a DPP4(i) with or without metformin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following a 2-week run-in period, sotagliflozin 400 mg (milligrams) administered as two 200 mg tablets and one placebo capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day for up to 26 weeks.
Drug: Sotagliflozin · Drug: Placebo
Following a 2-week run-in period, placebo matching sotagliflozin administered as two tablets (identical to sotagliflozin in appearance) and one capsule of empagliflozin 25 mg, once daily before the first meal of the day for up to 26 weeks.
Drug: Empagliflozin · Drug: Placebo
Following a 2-week run-in period, placebo was given as two placebo tablets (identical to sotagliflozin) and one placebo capsule (identical to empagliflozin) once daily before the first meal of the day for up to 26 weeks.
Drug: Placebo
Sotagliflozin 400 mg was administered as two tablets, once daily before the first meal of the day.
Also known as: SAR439954
Empagliflozin 25 mg capsule was administered, once daily before the first meal of the day.
Placebo was administered as two tablets (identical to sotagliflozin in appearance), once daily before the first meal of the day.
Placebo was administered as one capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day.
Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26
An analysis of covariance (ANCOVA) model was used for the analysis.
Time frame: Baseline, Week 26
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 12 in Participants With Baseline SBP ≥ 130 mmHg
An ANCOVA model was used for the analysis.
Time frame: Baseline, Week 12
Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Mixed Meal at Week 26
An ANCOVA model was used for the analysis.
Time frame: Baseline, Week 26
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26
An ANCOVA model was used for the analysis.
Time frame: Baseline, Week 26
Change From Baseline in Body Weight at Week 26
An ANCOVA model was used for the analysis.
Time frame: Baseline, Week 26
Change From Baseline in Sitting SBP at Week 12 for All Participants
An ANCOVA model was used for the analysis.
Time frame: Baseline, Week 12
Percentage of Participants With HbA1c <6.5% at Week 26
Time frame: Week 26
Percentage of Participants With HbA1c <7.0% at Week 26
Time frame: Week 26
Participants took part in the study at 160 investigative sites in Bulgaria, Canada, Czechia, France, Italy, Latvia, Mexico, Russian Federation, Slovakia, Spain, United Kingdom, and the United States from 27 November 2017 to 16 May 2019.
| Milestone | Sotagliflozin 400 mg | Empagliflozin 25 mg | Placebo |
|---|---|---|---|
| Started | 307 | 309 | 154 |
| Completed | 293 | 292 | 147 |
| Not completed | 14 | 17 | 7 |
| Withdrew: At the subject's own request | 11 | 12 | 5 |
| Withdrew: Adverse event | 1 | 2 | 1 |
| Withdrew: Poor compliance to protocol | 1 | 0 | 0 |
| Withdrew: Reason not specified | 1 | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
An analysis of covariance (ANCOVA) model was used for the analysis.
| percentage of HbA1c | Sotagliflozin 400 mg | Empagliflozin 25 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26 | -0.7 ± 0.1 | -0.8 ± 0.1 | -0.3 ± 0.1 |
An ANCOVA model was used for the analysis.
| mmHg | Sotagliflozin 400 mg | Empagliflozin 25 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 12 in Participants With Baseline SBP ≥ 130 mmHg | -5.6 ± 1.3 | -6.7 ± 1.3 | -3.5 ± 1.5 |
An ANCOVA model was used for the analysis.
| millimole per liter (mmol/L) | Sotagliflozin 400 mg | Empagliflozin 25 mg | Placebo |
|---|---|---|---|
| Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Mixed Meal at Week 26 | -1.3 ± 0.2 | -1.2 ± 0.9 | -0.4 ± 0.2 |
An ANCOVA model was used for the analysis.
| mmol/L | Sotagliflozin 400 mg | Empagliflozin 25 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 | -1.3 ± 0.2 | -1.6 ± 0.2 | -0.5 ± 0.2 |
An ANCOVA model was used for the analysis.
| kilogram (kg) | Sotagliflozin 400 mg | Empagliflozin 25 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 26 | -2.7 ± 0.3 | -3.2 ± 0.3 | -0.5 ± 0.3 |
An ANCOVA model was used for the analysis.
| mmHg | Sotagliflozin 400 mg | Empagliflozin 25 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Sitting SBP at Week 12 for All Participants | -1.7 ± 0.8 | -2.8 ± 0.8 | -0.4 ± 1.0 |
| percentage of participants | Sotagliflozin 400 mg | Empagliflozin 25 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With HbA1c <6.5% at Week 26 | 12.1 | 11.7 | 3.9 |
| percentage of participants | Sotagliflozin 400 mg | Empagliflozin 25 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With HbA1c <7.0% at Week 26 | 32.6 | 35.6 | 15.6 |
Collected over First dose of study drug to last dose of study drug (up to 26 weeks) + 4 weeks (Approximately 30 weeks). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sotagliflozin 400 mg | 0/307 (0%) | 10/307 (3.3%) | 58/307 (18.9%) |
| Empagliflozin 25 mg | 1/309 (0.3%) | 13/309 (4.2%) | 68/309 (22%) |
| Placebo | 0/154 (0%) | 9/154 (5.8%) | 39/154 (25.3%) |
| Event | Sotagliflozin 400 mg | Empagliflozin 25 mg | Placebo |
|---|---|---|---|
| PneumoniaInfections and infestations | 0/307 | 0/309 | 2/154 |
| Hypertensive crisisVascular disorders | 0/307 | 0/309 | 1/154 |
| Right ventricular failureCardiac disorders | 0/307 | 0/309 | 1/154 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/307 | 0/309 | 1/154 |
| Pulmonary massRespiratory, thoracic and mediastinal disorders | 0/307 | 0/309 | 1/154 |
| Cerebral ischaemiaNervous system disorders | 0/307 | 0/309 | 1/154 |
| Ischaemic strokeNervous system disorders | 0/307 | 0/309 | 1/154 |
| Intestinal obstructionGastrointestinal disorders | 0/307 | 0/309 | 1/154 |
| Duodenal ulcerGastrointestinal disorders | 0/307 | 0/309 | 1/154 |
| Skin ulcerSkin and subcutaneous tissue disorders | 0/307 | 0/309 | 1/154 |
| Event | Sotagliflozin 400 mg | Empagliflozin 25 mg | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 12/307 | 20/309 | 5/154 |
| HyperglycaemiaMetabolism and nutrition disorders | 6/307 | 6/309 | 9/154 |
| Any HypoglycaemiaMetabolism and nutrition disorders | 2/307 | 9/309 | 7/154 |
| HeadacheNervous system disorders | 7/307 | 8/309 | 6/154 |
| ConstipationGastrointestinal disorders | 3/307 | 5/309 | 6/154 |
| Urinary tract infectionInfections and infestations | 11/307 | 8/309 | 2/154 |
| DiarrhoeaGastrointestinal disorders | 10/307 | 8/309 | 5/154 |
| InfluenzaInfections and infestations | 5/307 | 9/309 | 5/154 |
| Vulvovaginal mycotic infectionInfections and infestations | 5/307 | 10/309 | 1/154 |
| Back painMusculoskeletal and connective tissue disorders | 6/307 | 3/309 | 4/154 |
Intent-to-treat (ITT) population included all randomized participants.
| Age, Continuous(years) | Sotagliflozin 400 mg | Empagliflozin 25 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 58.9 ± 9.7 | 59.7 ± 9.6 | 59.8 ± 9.6 | 59.4 ± 9.6 |
| Sex: Female, Male(Participants) | Sotagliflozin 400 mg | Empagliflozin 25 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 141 | 158 | 75 | 374 |
| Male | 166 | 151 | 79 | 396 |
| Ethnicity (NIH/OMB)(Participants) | Sotagliflozin 400 mg | Empagliflozin 25 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 56 | 66 | 33 | 155 |
| Not Hispanic or Latino | 251 | 243 | 121 | 615 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sotagliflozin 400 mg | Empagliflozin 25 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 18 | 21 | 8 | 47 |
| Asian | 17 | 11 | 4 | 32 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 0 | 2 |
| Black or African American | 13 | 13 | 5 | 31 |
| White | 256 | 257 | 137 | 650 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 6 | 0 | 7 |
| Hemoglobin A1c (HbA1c)(percentage of HbA1c) | Sotagliflozin 400 mg | Empagliflozin 25 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 8.23 ± 0.84 | 8.21 ± 0.93 | 8.21 ± 0.93 | 8.22 ± 0.90 |
| Systolic Blood Pressure (SBP)(millimeter of mercury (mmHg)) | Sotagliflozin 400 mg | Empagliflozin 25 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 134.55 ± 13.56 | 131.64 ± 12.18 | 133.19 ± 12.53 | 133.11 ± 12.87 |
Showing the first 100 of 160 sites across 12 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com
Ran from Nov 2017 to primary completion in May 2019, 17 months.
Results were first posted in May 2021, 1 year 11 months after primary completion. A results delay was requested in Apr 2020.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 17 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotagliflozin